710nok
2,5 %
Date:2024-04-26Time:17:30:00Latest report:Q4-2023List:Oslo BorsTicker:ULTI
Market Cap:244 mnokEnterprise Value:-19 mnokNet Sales:- mnokEarnings:-189,2 mnokEmployees:0ISIN:NO0010851603

Ratios

10-year key figure history for Ultimovacs turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Ultimovacs with index and moving average MA50 and MA200.

Stockprice:7,10
MA50:49,64
MA200:89,89
Price/MA200:-92,1 %
RSI (14):35,9
Price/MA50:-85,7 %

Description

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Pharmaceuticals